Ovarian Neoplasms
"Ovarian Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Descriptor ID |
D010051
|
MeSH Number(s) |
C04.588.322.455 C13.351.500.056.630.705 C13.351.937.418.685 C19.344.410 C19.391.630.705
|
Concept/Terms |
Ovarian Neoplasms- Ovarian Neoplasms
- Neoplasm, Ovarian
- Ovarian Neoplasm
- Ovary Neoplasms
- Neoplasm, Ovary
- Neoplasms, Ovary
- Ovary Neoplasm
- Neoplasms, Ovarian
Ovary Cancer- Ovary Cancer
- Cancer, Ovary
- Cancers, Ovary
- Ovary Cancers
- Ovarian Cancer
- Cancer, Ovarian
- Cancers, Ovarian
- Ovarian Cancers
- Cancer of Ovary
- Cancer of the Ovary
|
Below are MeSH descriptors whose meaning is more general than "Ovarian Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Ovarian Neoplasms".
This graph shows the total number of publications written about "Ovarian Neoplasms" by people in this website by year, and whether "Ovarian Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 3 | 0 | 3 | 1996 | 4 | 1 | 5 | 1997 | 1 | 0 | 1 | 1998 | 3 | 0 | 3 | 1999 | 1 | 1 | 2 | 2000 | 2 | 0 | 2 | 2002 | 0 | 1 | 1 | 2003 | 3 | 1 | 4 | 2004 | 3 | 1 | 4 | 2005 | 5 | 1 | 6 | 2006 | 1 | 0 | 1 | 2007 | 10 | 0 | 10 | 2008 | 7 | 3 | 10 | 2009 | 4 | 0 | 4 | 2010 | 5 | 5 | 10 | 2011 | 11 | 2 | 13 | 2012 | 9 | 1 | 10 | 2013 | 10 | 1 | 11 | 2014 | 6 | 1 | 7 | 2015 | 11 | 2 | 13 | 2016 | 21 | 1 | 22 | 2017 | 14 | 0 | 14 | 2018 | 12 | 3 | 15 | 2019 | 20 | 0 | 20 | 2020 | 21 | 1 | 22 | 2021 | 19 | 2 | 21 | 2022 | 23 | 1 | 24 | 2023 | 18 | 0 | 18 | 2024 | 16 | 3 | 19 | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Ovarian Neoplasms" by people in Profiles.
-
Lawson-Michod KA, Marks JR, Collin LJ, Nix DA, Davidson NR, Huff CD, Yu Y, Atkinson A, Johnson CE, Salas LA, Peres LC, Greene CS, Schildkraut JM, Doherty JA. Genomic Characterization of High-Grade Serous Ovarian Carcinoma Reveals Distinct Somatic Features in Black Individuals. Cancer Res. 2025 May 02; 85(9):1725-1737.
-
Alqaisi HA, Cohn DE, Chern JY, Duska LR, Jewell A, Corr BR, Winer IS, Girda E, Crispens MA, Dhani NC, Madariaga A, Grant RC, Malaguti M, Lee C, Bowering V, Wong H, Poothullil A, Speers V, Wang L, Bedard PL, Brady JC, Nixon AB, Chen L, O'Connor C, Zamboni W, McKee T, Moscow JA, Oza AM, Lheureux S. Randomized Phase II Study of Bevacizumab with Weekly Anetumab Ravtansine or Weekly Paclitaxel in Platinum-Resistant/Refractory High-Grade Ovarian Cancer (NCI Trial). Clin Cancer Res. 2025 Mar 17; 31(6):993-1001.
-
Villagomez FR, Lang J, Nunez-Avellaneda D, Behbakht K, Dimmick HL, Webb PG, Nephew KP, Neville M, Woodruff ER, Bitler BG. Claudin-4 Stabilizes the Genome via Nuclear and Cell-Cycle Remodeling to Support Ovarian Cancer Cell Survival. Cancer Res Commun. 2025 01 01; 5(1):39-53.
-
Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, Schallenkamp JM, Adra N, Appleman LJ, Alden M, Thomes Pepin J, Ellerton JA, Poklepovic A, Walter A, Rampurwala MM, Robinson WR, Kim HS, Chung LI, McLeod CM, Lopez G, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R. SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer. Clin Cancer Res. 2024 Dec 16; 30(24):5593-5600.
-
Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, To F, Lin S, Villagomez FR, Jeong AD, Guntupalli SR, Behbakht K, Gibaja V, Arnoult N, Chuong EB, Bitler BG. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner. Mol Cancer Res. 2024 12 03; 22(12):1117-1127.
-
Alvarez Secord A, Lewin SN, Murphy CG, Cecere SC, Barqu?n A, G?lvez-Montosa F, Mathews CA, Konecny GE, Ray-Coquard I, Oaknin A, Rubio P?rez MJ, Bonaventura A, Diver EJ, Ayuk SM, Wang Y, Corr BR, Salutari V. The efficacy and safety of mirvetuximab soravtansine in FRa-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial. Ann Oncol. 2025 Mar; 36(3):321-330.
-
Lin S, Nguyen LL, McMellen A, Leibowitz MS, Davidson N, Spinosa D, Bitler BG. Leveraging Multi-omics to Disentangle the Complexity of Ovarian Cancer. Mol Diagn Ther. 2025 Mar; 29(2):145-151.
-
Van Kleunen LB, Ahmadian M, Post MD, Wolsky RJ, Rickert C, Jordan KR, Hu J, Richer JK, Brubaker LW, Marjon N, Behbakht K, Sikora MJ, Bitler BG, Clauset A. The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma. Cancer Immunol Res. 2024 Nov 04; 12(11):1492-1507.
-
Richardson DL, Quintanilha JCF, Danziger N, Li G, Sokol E, Schrock AB, Ebot E, Bhardwaj N, Norris T, Afghahi A, Frachioni A, Washington C, Dockery L, Elvin J, Graf RP, Moore KN. Effectiveness of PARP Inhibitor Maintenance Therapy in Ovarian Cancer by BRCA1/2 and a Scar-Based HRD Signature in Real-World Practice. Clin Cancer Res. 2024 Oct 15; 30(20):4644-4653.
-
Liu J, Berchuck A, Backes FJ, Cohen J, Grisham R, Leath CA, Martin L, Matei D, Miller DS, Robertson S, Barroilhet L, Uppal S, Hendrickson AW, Gershenson DM, Gray HJ, Hakam A, Jain A, Konecny GE, Moroney J, Ratner E, Schorge J, Thaker PH, Werner TL, Zsiros E, Behbakht K, Chen LM, DeRosa M, Eisenhauer EL, Leiserowitz G, Litkouhi B, McHale M, Percac-Lima S, Rodabaugh K, Vargas R, Jones F, Kovach E, Hang L, Ramakrishnan S, Alvarez RD, Armstrong DK. NCCN Guidelines? Insights: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 10; 22(8):512-519.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|